All tags RabMAb Why a RabMAb® primary isn’t the same as any other antibody

Calponin antibody (ab46794)

Why a RabMAb® primary isn’t the same as any other antibody

Rabbit monoclonal antibodies combine the superior antigen recognition of a rabbit antibody with the specificity and consistency of a monoclonal.

RabMAb primary antibodies are generated using a unique and proprietary method of monoclonal antibody development from rabbits rather than the conventional method of starting with mice or rats.

The basic principle for making a RabMAb primary antibody is the same as for mouse monoclonals. Proprietary rabbit fusion partner cells can fuse to rabbit B-cells to create the Rabbit Hybridoma cells, true rabbit-to-rabbit hybridomas (1).

Hybridomas are then screened to select for clones with specific and sensitive antigen recognition and the antibodies are characterized using a variety of methods (view the process of RabMAb creation below).

Unlike traditional  murine antibodies, antibodies generated with RabMAb technology provide better antigen recognition (2). The reason for this is that the rabbit immune system generates antibody diversity and optimizes affinity by mechanisms that are more efficient than those of mice and other rodents. This increases the possibility of obtaining a functional antibody that will work in a variety of applications (3, 4).

Additionally, many small compounds and peptides do not elicit a good immune response in mice but do favorably in rabbits. It is often for this reason that rabbit polyclonal antibodies are developed and used in many research and diagnostic applications, ranging from drug screening to clinical diagnosis.

In conclusion, RabMAb primary antibodies bring the combined benefits of superior antigen recognition of a rabbit immune system with the specificity and consistency of a monoclonal antibody, providing antibodies with superior binding affinity and bioactivity in a wide variety of biological assays.

View the process of RabMAb creation.

View all RabMAb advantages

Patented technology

Our RabMAb technology is currently the only available hybridoma-based technology for making rabbit monoclonals and covered under the following U.S. Patents, No. 5,675,063 and 7,429,487. Our broad patents cover not only the rabbit fusion partner cell line but also the method for generating rabbit fusion partner cell line as well as the antibodies produced from the cell line.

References

  • 1. Rabbit monoclonal antibodies: generating a fusion partner to produce rabbit-rabbit hybridomas.
    H Spieker-Polet, P Sethupathi, P C Yam, and K L Knight, Proc Natl Acad Sci 92(20): 9348–9352.
  • 2. Rabbit monoclonal antibodies: a comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies.
    Rossi S, Laurino L, Furlanetto A, Chinellato S, Orvieto E, Canal F, Facchetti F, Dei Tos AP. Am J Clin Pathol. 2005 Aug;124(2):295-302.
  • 3. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen
    Rocha R, Nunes C, Rocha G, Oliveira F, Sanches F, Gobbi H. Pathol Res Pract. 2008;204(9):655-62. doi: 0.1016/j.prp.2008.03.010. Epub 2008 Jun 18.
  • 4. Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.
    Van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20.